



NOTICE

Metrocare Services, **Quality and Authority Services Committee will meet on Thursday, December 1, 2016 at 12:45 p.m.** The meeting will be held at 1345 River Bend Dr./Dallas, Texas 75247 (Mustangs Conference Room).

If you need additional assistance to effectively participate in or observe this meeting, please notify the Administrative Office at 214.743.1201, at least 72 hours prior to this meeting, so that reasonable accommodations can be made to assist you.

The attached agenda items will be discussed/acted upon. A portion of the meeting may be closed as allowed by Subchapter D, Sections 551.071 - 551.075 to discuss personnel matters, litigation, acquisition of real property, for the purpose of discussing negotiated contracts for prospective gifts or donations to the Center when such discussions would have a detrimental effect on the negotiating position of the Center and a third person, firm or corporation, and to receive information from and/or question employee(s) without deliberating on the subject matter.

Dr. Brenda Richardson Rowe, Chairman
Quality and Authority Services Committee

Mrs. Jill L. Martinez,
Madame Chairman, Board of Trustees

By: Martha L. Toscano
Executive Assistant to the CEO/Board Liaison

METROCARE SERVICES

Quality and Authority Services Committee Meeting
Thursday, December 1, 2016 at 12:45 pm
1345 River Bend Drive / Dallas, TX 75247

Mustangs Conference Room

Committee Members:

Dr. Brenda Richardson Rowe, Madame Chairman
Ms. Dee Salinas
Chief Norman Seals
Ms. Jill L. Martinez, ex officio

Dr. Richardson Rowe

I. CALL TO ORDER

II. CITIZEN COMMENTS (Please limit to 3 minutes)

III. ISSUES TO BE CONSIDERED

1. ❖ Acceptance of the September 10, 2016 Quality and Authority Services Committee Meeting Minutes.

QUALITY MANAGEMENT REPORTS

Linda Thompson

2. ❖ Recommendation of Acceptance of Quality Management Report for October 2016

The chief operating officer will present the performance of the Dallas County Local Authority (LA), a part of the Center, including its financial performance, its clinical performance, and its performance on quality oversight, and also management plans to address deficiencies therein.

- ❖ *Designates items on which the Board may take action*